AML is a malignant neoplasm of myeloid lineage cells arising within the bone marrow and is the most common acute leukemia in adults. Current treatment for AML is combination chemotherapy and some patients also require a stem cell transplant. Stem cell transplants carry serious risks including graft-versus-host disease (GvHD). Many patients can have disease relapse despite undergoing a stem cell transplant, necessitating improved treatments.
Marker’s lead product candidate, a multi-antigen targeted T-cell treatment for patients with AML, is currently being evaluated in a Phase 2 multicenter trial in patients with AML after a stem cell transplant.
Unlike other therapies, Marker’s approach has the potential to target multiple cancer cells within a tumor, which may reduce the risk of tumor evasion. Data from a Phase 1 clinical trial demonstrated the potential clinical benefit mediated by the infused T cell product, which allows the patient’s own immune system to participate in the anti-tumor effect.1
1Biology of Blood Marrow Transplantation, 23 (2017) S18–S391. DOI: 10.1016/j.bbmt.2016.12.100